CHARLOTTE, N.C., Aug. 26, 2008 (GLOBE NEWSWIRE) (PRIME NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Droxidopa for the treatment of symptomatic neurogenic orthostatic hypotension (NOH).
